200 related articles for article (PubMed ID: 23620238)
21. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
22. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
23. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.
Nandeesha H; Koner BC; Dorairajan LN; Sen SK
Clin Chim Acta; 2006 Aug; 370(1-2):89-93. PubMed ID: 16516184
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.
Robert G; Smit F; Hessels D; Jannink S; Karthaus HF; Aalders T; Jansen K; de la Taille A; Mulders PF; Schalken JA
Prostate; 2011 Nov; 71(15):1701-9. PubMed ID: 21446005
[TBL] [Abstract][Full Text] [Related]
25. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
26. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Vignozzi L; Morelli A; Sarchielli E; Comeglio P; Filippi S; Cellai I; Maneschi E; Serni S; Gacci M; Carini M; Piccinni MP; Saad F; Adorini L; Vannelli GB; Maggi M
J Endocrinol; 2012 Jan; 212(1):71-84. PubMed ID: 22010203
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation.
Wang W; Bergh A; Damber JE
Prostate; 2007 Aug; 67(11):1238-46. PubMed ID: 17570496
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
[TBL] [Abstract][Full Text] [Related]
29. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
Grosman H; Fabre B; Mesch V; Lopez MA; Schreier L; Mazza O; Berg G
Aging Male; 2010 Jun; 13(2):87-92. PubMed ID: 19921964
[TBL] [Abstract][Full Text] [Related]
30. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Cellai I; Vignozzi L; Yehiely-Cohen R; Maneschi E; Gacci M; Carini M; Adorini L; Vannelli GB; Maggi M
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):80-92. PubMed ID: 22406511
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor isoforms in human and rat prostate.
Xia SJ; Hao GY; Tang XD
Asian J Androl; 2000 Dec; 2(4):307-10. PubMed ID: 11202423
[TBL] [Abstract][Full Text] [Related]
32. Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats.
Funahashi Y; Wang Z; O'Malley KJ; Tyagi P; DeFranco DB; Gingrich JR; Takahashi R; Majima T; Gotoh M; Yoshimura N
Prostate; 2015 Mar; 75(4):381-9. PubMed ID: 25451715
[TBL] [Abstract][Full Text] [Related]
33. Expression of proteinase-activated receptor-2 (PAR2) is androgen-dependent in stromal cell line (hPCPs) from benign prostatic hyperplasia.
Mannowetz N; Würdinger R; Zippel A; Aumüller G; Wennemuth G
Prostate; 2010 Sep; 70(12):1350-8. PubMed ID: 20623639
[TBL] [Abstract][Full Text] [Related]
34. Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia.
Vanella L; Russo GI; Cimino S; Fragalà E; Favilla V; Li Volti G; Barbagallo I; Sorrenti V; Morgia G
Urology; 2014 Jun; 83(6):1444.e7-13. PubMed ID: 24862399
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit.
Morelli A; Comeglio P; Filippi S; Sarchielli E; Vignozzi L; Maneschi E; Cellai I; Gacci M; Lenzi A; Vannelli GB; Maggi M
Prostate; 2013 Mar; 73(4):428-41. PubMed ID: 22996758
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor β-receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation.
Descazeaud A; Weinbreck N; Robert G; Vacherot F; Abbou CC; Labrousse F; Allory Y; Rubin MA; de la Taille A
BJU Int; 2011 Jul; 108(2 Pt 2):E23-8. PubMed ID: 20840324
[TBL] [Abstract][Full Text] [Related]
37. Testosterone and Benign Prostatic Hyperplasia.
Rastrelli G; Vignozzi L; Corona G; Maggi M
Sex Med Rev; 2019 Apr; 7(2):259-271. PubMed ID: 30803920
[TBL] [Abstract][Full Text] [Related]
38. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
39. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
Hsieh JT; Chen SC; Yu HJ; Chang HC
Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of NKX3.1 in benign prostatic hyperplasia.
Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
